A New Publication Covering The CELL AND GENE THERAPY INDUSTRY
The Best Way to Keep up with the Growing Cell and Gene Therapy Industry
From Science and Medicine Group, the company behind Instrument Business Outlook, Kalorama Information, SDi and other publications, comes a new publication: Cell and Gene Therapy Business Outlook.
With thousands of potential therapies on the market, cell and gene therapy promises future potential for pharmaceutical developers and those serving them.
A new twice-monthly publication dedicated to cell and gene therapy, Cell and Gene Therapy Business Outlook will offer the following:
Market Sizing and Forecasting of CGT Markets in Every Issue
Executive News Summaries – What is Happening in CGT Markets and Why It Matters
Deals Between CGT Companies Tracked in Every Issue
Important Science That Will Shape Tomorrow’s Business
Updates on Pipelines and Important Clinical Trials
Cell and Gene Therapy Tools, CMOs, Manufacturing Developments
Market Analysis of a Cell and Gene Therapy Segment in Every Issue
There are many websites, publications and sources on cell therapy. Cell and Gene Therapy Business Outlook differs from these sources in that it is created by market researchers and editors focused on business opportunity. Each issue will track the market size and potential for a key market segment.
Who Is Dealing with Whom? Tracking of Cell and Gene Company Deals In Every Issue.
There is a never-ending stream of activities in this market. How can you keep up? Each issue of Cell and Gene Therapy Business Outlook will keep track of mergers, investments, licensing, technology transfers and partnerships in the industry. Each issue of Cell and Gene Therapy Business Outlook contains an updated CGT Recent Deals Table with information on these important events.
Future issues will also analyze of the number of deals and increases or decreases in activity as a measure of business. You’ll never miss an important happening with Cell and Gene Therapy Business Outlook. Also, the Recent Deals Table is a great resource for tracking companies in the market.
The News That Matters
Edited by Blake Middleton, a professional CGT researcher and former Staff Research Associate at UCLA Department of Pharmacology, Cell and Gene Therapy Business Outlook is designed to provide the most relevant news. Included is news that could affect business decisions near-term. Cell and Gene Therapy Business Outlook also explains the relevant science.
With a focus on what the recent news of the day means for business, our curated news and news analysis means that you and your organization can be confident you won’t miss an important development in cell and gene therapy.
Convenient and Cost-Effective Seat-Based Pricing: Pricing depends on the number of users. Subscriptions can be as low as $2,200 annually for a limited one-person (single user) subscription.
Open up access: If more than one person will be reading, you can unlock access to other members of your organization. It’s easy to do: team subscription prices are as little as $4,995 annually for up to five readers. Larger team? Other licenses are available. Consult our website. Convenient and Cost-Effective Seat-Based Pricing: Pricing depends on the number of users. Subscriptions can be as low as $2,200 annually for a limited one-person (single user) subscription.
___________________________________________
THE CELL AND GENE THERAPY MARKET IN ONCOLOGY is $1,582M
MARKET SIZE: The global market for cell and gene therapy for oncology reached $1,582 million in 2020 and is expected to climb to $2,744 for 2021.
There are over 100 different types of cancer; some of the more prominent include lung, breast, brain, blood, prostate and colon cancer. The immune system plays a primary role in the body’s defense against malignancy. Although a tumor is derived from the body’s own cells and is expected to possess proteins that are recognized as self and nonantigenic, neoplastic cells can express antigens that are not recognized as self. These cells can often be eliminated by the immune system.
FORECAST: projected to increase to $7,391 in 2025; $17,490 million by 2030.
Treating cancer is difficult because it is not a single disease and because all the cells in a single tumor do not behave in the same way. Although most cancers are thought to be derived from a single abnormal cell, by the time a tumor reaches a clinically detectable size, the cancer may contain a diverse population of cells.
Market Forecast: Strong increases in the CAR-T therapy market, increasing from just $16 million in 2017 to $1,081 million in 2020 and projected to increase to $7,391 in 2025; $17,490 million by 2030. Blood cancers are the leading driver in the segment, representing 68% of total sales. This is expected to be the primary segment through the forecast, representing 80% of sales by 2025 and 80% in 2030. The United States and Europe are the largest markets due to overall product approvals and cost associated with the therapies. The US market represented nearly 77%, while Europe represented 19% in 2020. Gilead and Novartis combined represent 68% of the market for cell and gene therapy in oncology. Industry refocuses on oncology cell and gene therapies in a post-pandemic arena, returning to pre-pandemic growth.
___________________________________________
AAV CAPSID DISCOVERY UPDATE
Adeno-associated viruses (AAV) are small human viruses which provoke only a mild immune response and are not known to cause any human disease. AAVs are quite simple in organization, possessing a small (4.7kb) single-stranded DNA genome with only two open reading frames (ORFs), rep and cap, flanked by short (145 base) inverted terminal repeats (ITRs). The rep ORF encodes multiple overlapping sequences for proteins required for replication, and the cap ROF does the same for capsid proteins, which are the proteins forming the outer viral protein coat. These genes alone are not sufficient for viral replication, and AAVs require co-infection with a second, helper virus (such as an adenovirus or HSV) to supply the remaining gene products for replication (hence the name adeno-associated virus).
Gene therapy AAV vectors are further modified to remove the rep and cap genes from the viral genome (along with their promoters and polyadenylation signal), replacing them with a therapeutic expression cassette. Production of recombinant AAV vectors in cell lines requires the rep and cap genes to be supplied by a plasmid transfected in trans, in addition to the genes supplied by the helper virus. None of these externally supplied viral genes are packaged into the final construct, so the resulting viral delivery vehicle consists only of the therapeutic cassette encased in an AAV capsid, without any viral genes present. The gene therapy vector is therefore incapable of replication, even with co-infection by a suitable helper virus.
In addition to their safety, AAV vectors possess many features which make them attractive gene therapy candidates. They have extremely low immunogenicity, they can infect both dividing and non-dividing cells, and they can persist outside the genome to offer stable, long-term expression without the risks associated with host genome integration.
AAV vectors also suffer from several shortcomings, however:
• Because of their wide distribution, many individuals have already been exposed to naturally occurring AAV serotypes and produce immune responses against them.
• AAV vectors cannot reach most tissues efficiently, and do not spread easily within those tissues if they do.
• Vectors will preferentially target some cell types but not others.
• Transduction efficiency is often extremely low.
Each of these shortcomings can be addressed by innovations in capsid structure. In addition to protecting the DNA payload, the capsid is responsible for binding to specific receptors on the target cell and safely delivering the DNA payload to the cell machinery that so will be transported to the nucleus. Viral packaging efficiency, host immunological response, tissue and cell type specificity, and transduction efficiency are all determined by the capsid serotype. Unfortunately, initial gene therapy experiments were restricted to a handful of natural AAV serotypes which had limited tropism in many human cell types. Common serotypes also present problems with pre-existing immunity (PEI), as up to 90% of the human population have already been exposed to at least one AAV serotype. For these reasons, novel capsid discovery is a current hotbed of gene therapy research.
More information on this topic can be found in the latest issue. SUBSCRIBE TODAY
THE LATEST NEWS FROM CELL AND GENE THERAPY OUTLOOK
The following are recent developments in Cell and Gene Therapy, from Volume 1, Issue 13 of Cell and Gene Therapy Business Outlook, published December 22, 2021
Arrowhead Pharmaceuticals, based in Pasadena, CA, has completed a purchase of 13 acres in the Verona Technology Park in Verona, WI, where it plans to invest between $200 million and $250 million to build a 140,000 square-foot drug manufacturing facility and a 115,000 square-foot laboratory and office facility to support its process development and analytical activities, creating about 250 new jobs in the local area. The company expects to begin construction is in the first quarter of 2022, with completion of the lab and office space anticipated in the first quarter of 2023, and the manufacturing facility in the fourth quarter of 2023. The new Arrowhead campus will support the company’s growing pipeline and establish manufacturing capabilities for its targeted RNAi molecule (TRiM) drug candidates while the company continues to operate its R&D facilities in Madison, WI, and San Diego, CA. Arrowhead’s TRiM platform treats genetic diseases by using RNA interference (RNAi) to silence the genes that cause them.
Abeona Therapeutics, New York-based a gene and cell therapy company, has announced the pricing of an underwritten public offering of 44,700,000 shares and warrants to purchase 44,700,000 shares at a price of $0.39 per one share of stock and one warrant to purchase one share. The warrants have an exercise price of $0.39 per share and can be exercised immediately, with an expiration date five years from the date of issuance. The offering is expected to close on December 21, 2021, with proceeds of approximately $17.5 million. Abeona will use the funds to continue clinical development of pipeline products which include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa currently in Phase III development; ABO-102, an AAV-based gene therapy for Sanfilippo syndrome type A (MPS IIIA) currently in Phase I/II development; ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B (MPS IIIB) currently in Phase I/II development; and preclinical programs for indications in juvenile Batten disease (CLN3), cystic fibrosis (CF), retinal diseases, and undisclosed targets.
Spark Therapeutics, a Roche company based in Philadelphia, PA, has announced plans to invest $575 million to build a new, state-of-the-art gene therapy center on Drexel University’s campus. The center will be located at the intersection of 30th and Chestnut Streets, with a 99-year ground lease of Drexel University’s F Lot. The planned 500,000 square-foot multi-story building will more than double Spark’s campus in Philadelphia to a projected one million square feet. The announcement kicks off a long-term partnership between Spark and Drexel University, and the new facility is anticipated to begin construction in the fourth quarter of 2022.
BioMarin Pharmaceutical, based in San Rafael, CA, and Skyline Therapeutics (formerly Geneception), based in Shanghai, China, have announced a multi-year strategic collaboration to discover, develop, and commercialize adeno-associated virus (AAV)-based gene therapies for genetic cardiovascular diseases. Skyline Therapeutics’ proprietary AAV vector engineering and design technology and manufacturing capability will be combined with BioMarin’s experience in gene therapy development, cardiovascular biology, and insights into genetic diseases to develop gene therapies targeting dilated cardiomyopathies (DCM), a group of progressive diseases which result in an enlarged heart with reduced circulatory efficiency. Under the agreement, BioMarin and Skyline will collaborate on discovery and research through to IND application, after which each company will be responsible for clinical development in their pre-defined territories (United States, Europe, and Latin America for BioMarin, and the Asia-Pacific region for Skyline). Skyline Therapeutics will receive an undisclosed upfront payment and an equity investment from BioMarin, along with potential milestone payments and royalties on future sales by BioMarin in its territories.
Chugai Pharmaceutical, based in Tokyo, Japan, has announced a license agreement with Basel, Switzerland-based Roche for delandistrogene moxeparvovec (SRP-9001), an investigational gene therapy for Duchenne muscular dystrophy (DMD) currently being developed by Roche and Cambridge, MA-based Sarepta Therapeutics. Under the agreement, Chugai will have exclusive marketing rights in Japan for delandistrogene moxeparvovec in exchange for an upfront fee and milestone payments. Sarepta and Roche are currently conducting a global Phase III clinical trial for delandistrogene moxeparvovec for the treatment of DMD, and Sarepta will handle future clinical studies, including in Japan. Chugai will be responsible for the regulatory filing and marketing in Japan.
Philadelphia, PA-based iECURE, has announced that it has entered into an exclusive agreement with the University of Pennsylvania (Penn) to develop next-generation lipid nanoparticles (LNP) for liver gene editing applications. The agreement grants iECURE exclusive rights to gene editing in the liver using LNP technology developed in collaboration with the laboratory of Michael Mitchell, PhD, at Penn. New startup iECURE is a mutation-agnostic in vivo “knock-in” gene editing company, and was founded in 2020 in collaboration with Penn’s Gene Therapy Program, directed by James M. Wilson, MD, PhD. Mitchell’s laboratory has already collaborated for many years with Penn’s Gene Therapy Program and will continue that collaboration with the new partnership. The new agreement expands iECURE potential pipeline of programs with Penn from 13 to 15.
Inceptor Bio, based in Research Triangle Park, NC, has announced that it has executed an in-licensing agreement with the University of California, Santa Barbara (UCSB) for a chimeric antigen receptor macrophage (CAR-M) technology invented by the laboratory of Denise Montell, PhD. Macrophages play a key role in innate immunity, attacking and engulfing (through a process called phagocytosis) anything that does not display surface markers characteristic of healthy cells. They also initiate adaptive immune responses by displaying antigens and secreting cytokines to recruit other immune cells. CARs combine the functions of tumor-specific antigen binding and macrophage activation into a single receptor molecule, and program the macrophages to selectively target and engulf cancer cells. The macrophages then recruit other cells to generate a coordinated immune response against the cancer cells, attacking even difficult-to-treat solid tumors.
New York-based Pfizer has announced the opening of a new 85,500 square-foot clinical manufacturing facility in Durham, NC, part of its $800 million investment to build three scalable, state-of-the-art gene therapy manufacturing facilities with 300,000 square feet of capacity to support its continued investment in that field. The new facility will house Pfizer’s BioTherapeutics Pharmaceutical Sciences Group and is expected to create more than 50 new jobs supporting Pfizer’s gene therapy and biologics portfolio, with approximately 40 employees relocating from Pfizer’s Chapel Hill site. With these investments, Pfizer has built up one of the world’s largest production capacities for gene therapy vectors, with a total bioreactor manufacturing capacity of 22,000 liters. Pfizer’s worldwide R&D capacity includes locations in La Jolla, CA; Boulder, CO; St Louis, MO; Pearl River, NY; Groton, CT; and Cambridge and Andover, MA.
Genenta Science, a clinical-stage biotech company based in Milan, Italy, has gone public, selling 2.4 million American depositary shares (ADSs), at $11.50 each to generate total proceeds of about $36 million. Genenta specializes in hematopoietic stem-cell gene therapies for the treatment of solid tumor cancers, and its lead candidate, Temferon, is currently in a Phase I/IIa dose-escalation clinical trial for the treatment of newly diagnosed glioblastoma multiforme (GBM), a common brain cancer. Temferon modifies autologous hematopoietic stem and progenitor cells (HSPCs) by ex vivo gene transfer to create tumor-infiltrating Tie2 expressing monocytes (TEMs) which carry a payload of IFN-α, a proinflammatory therapeutic.
Myrtelle, based in Wakefield, MA, has announced that it entered into an exclusive worldwide licensing agreement with New York-based Pfizer for rAAV-Olig001-ASPA, an investigational recombinant adeno-associated virus (rAAV)-based gene therapy for the treatment of Canavan disease. Canavan disease is a fatal childhood genetic neurological disorder caused by a defective ASPA gene encoding the enzyme aspartoacylase. Aspartoacylase deficiency interferes with growth of the myelin sheath around the nerve fibers of the brain, resulting in spongy degeneration of the white matter in the brain. The investigational gene therapy targets oligodendrocytes, which responsible for producing myelin, directly with a proprietary AAV vector designed to restore ASPA gene function. Myrtelle is currently conducting a Phase I/II clinical of the gene therapy in children with Canavan disease at Dayton Children’s Hospital in Dayton, Ohio.
Neochromosome, a wholly owned subsidiary of Opentrons Labworks based in New York, and Mekonos, based in San Francisco, CA, have formed a new partnership to advance cell engineering for personalized cell therapies. The partnership will test and optimize the delivery of Neochromosome’s de novo synthesized “Big-DNA” cargo directly into the nuclei of human induced pluripotent stem cells (hiPSCs) using Mekonos’ proprietary Iris technology for ex vivo delivery of large DNA payloads. The companies say their cell-based therapies have the potential to treat a variety of diseases, including diabetes, Parkinson’s, and cancer. The research collaboration launches in January 2022 in the San Francisco Bay Area, with initial results expected mid-year.
Novartis, based in Basel, Switzerland, has terminated its agreement with Melbourne, Australia-based Mesoblast to develop, commercialize and manufacture remestemcel-L for the treatment of acute respiratory distress syndrome (ARDS), including that associated with COVID-19. Remestemcel-L is an investigational cell therapy composed of culture-expanded allogeneic mesenchymal stromal cells (MSCs) derived from bone marrow of an unrelated donor. The treatment had previously been rejected by the FDA for the treatment of graft-vs-host disease in late 2020, but Mesoblast had hopes that a 300-patient, Phase III clinical trial evaluating Remestemcel-L for the treatment of COVID-19-related ARDS would lead to an Emergency Use Authorization (EUA) by the FDA. The clinical trial failed to meet its primary endpoint, however, and Novartis has backed out the deal. Based on the trial’s observed mortality reduction with remestemcel-L in patients aged under 65 with COVID-related ARDS, Mesoblast is still optimistic about the drug’s potential, and is preparing to launch another Phase III trial in order to pursue an EUA for the treatment of COVID-related ARDS.
Accellix, based in Jerusalem, Israel, has raised $10 million from BroadOak Capital Partners. Accellix is a biotechnology company that provides flow cytometry results in a compact, easy-to-use platform for use by cell therapy companies on the manufacturing floor and at the point-of-need. Their products streamline a complex but necessary part of cell analysis, providing more robust outcomes and reducing overall quality-control costs in cell therapy manufacturing. The investment is part of BroadOak’s fifth fund and marks the firm’s third investment in the last six months in the rapidly growing market of tools and services for cell and gene therapy development and manufacturing. BroadOak previously invested in Accellix as part of a prior fund.
Rejuveron Life Sciences, a Zürich-based biotech company, has funded a further $20 million in Francisco-based Endogena Therapeutics’ $29 million Series A financing, strengthening its support to a near-majority holding. Endogena specializes in endogenous regenerative therapeutics targeting degenerative diseases of the eye, and Endogena will use the funding to advance its two lead programs. EA-2353 is an endogenous photoreceptor regeneration treatment for retinitis pigmentosa (RP) and is scheduled to enter human trials in the first half of 2022. EA-2351 is a pre-clinical treatment for geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD).
Cambridge, MA-based bluebird bio’s investigational therapy bb1111 (lovotibeglogene autotemcel) is beginning to show promising results as a potential permanent cure for sickle cell disease (SCD). In a Dec 12 paper published in The New England Journal of Medicine, researchers led by Julie Kanter, MD, at the University of Alabama at Birmingham (UAB) report that patients treated with bb1111 are showing signs of stable expression of normal hemoglobin. The therapy consists of autologous transplantation of hematopoietic stem and progenitor cells (HSPCs) transduced with the BB305 lentiviral vector encoding HbAT87Q, a modified β-globin gene which produces a form of hemoglobin less likely to cause sickling when it’s expressed alongside the mutated hemoglobin gene responsible for SCD (HbS). A few days after publication of those results, bluebird announced that the FDA had placed a partial, temporary clinical hold on the gene therapy due to an ongoing investigation by bluebird into an adolescent patient with persistent, non-transfusion-dependent anemia following treatment with the drug. Enrollment and dosing for SCD patients 18 and older are unaffected by the hold, and those studies will continue as planned.
Smart Immune, based in Paris, France, has announced a research collaboration with New York’s Memorial Sloan Kettering Cancer Center (MSK). The clinical-stage company specializes in a proprietary ex-vivo biomimetic “thymus-in-a-dish” technology to create ProTcells, which are allogeneic T-cell progenitors designed to reset a rapid, safe, and full immune reconstitution. The MSK collaboration will expand Smart Immune’s ProTcell pipeline with a CAR-ProTcell platform which uses its progenitor ProTcells instead of mature T-cells to generate a naïve, long lasting, exhaustion-free CAR-T cell population. MSK will develop the first mouse-to-mouse model CAR-ProTcell proof-of-concept, and Smart Immune will handle the humanized model proof-of-concept. The company says the work has the potential to expedite the clinical development of next generation CAR-T cells combining long-term persistence, natural protection against infections, and low risk of graft-versus-host disease (GvHD) in allogeneic setting.
Aziyo Biologics, a commercial-stage regenerative medicine company based in Silver Spring, MD, has announced the closing of approximately $14.0 million of previously announced private investment in public equity (PIPE) financing. The financing was led by a fund affiliated with Birchview Capital, with participation from existing investors including funds affiliated with Deerfield Management Company and HighCape Capital. Aziyo specializes in products to improve outcomes for patients undergoing cardiovascular, orthopedic, and reconstructive surgery, with a focus on patients receiving implantable medical devices.
PDC*line Pharma, a clinical stage biotech company based in Liège, Belgium and Grenoble, France has announced the completion of its Series B2 round of financing, €11.8 million ($13.7 million) in financing was led by Korea Investment Partners, a leading multi-billion dollar South-Korean fund, and also included a syndicate of new South Korean investors in life sciences: Alpha Holdings, Brain Asset Management, and Hansongneotech Co. Ltd. Existing investors Noshaq Group (ex-Meusinvest), Sambrinvest (the Charleroi investment fund), SFPI-FPIM (the Belgian Federal Holding and Investment Company), SRIW (The Regional Investment Company of Wallonia), and Smart Korea UTC BioHealthcare Venture Fund also participated. The company has also received a €5.7M ($6.6M) grant in repayable aid from the Walloon Region of Belgium, bringing the B2 round total to €17.5 million ($20.3 million). Together with €20 million ($23.2 million) in B1 fundraising from January 2020, the company has raised a total of €37.5M million in this Series B round. The company’s lead candidate, PDC*lung01, consists of PDC*line’s professional antigen-presenting cells loaded with HLA-A2 restricted peptides derived from seven shared tumor antigens, and is currently in a Phase Ib/II clinical trial for the treatment of non-small cell lung cancer.
TrinCE, a new spin-off of Ghent University (UGent) based in Ghent, Belgium, has raised €4 million ($4.5 million) from Novalis Biotech Acceleration, Qbic II, and private investors. The company’s LumiPore transfection platform uses photothermal nanoparticles in combination with laser illumination to transiently heat and permeabilize cell membranes. The platform has demonstrated efficient cytosolic delivery of a wide variety of molecules up to 500 kDa, including antisense oligonucleotides (ASOs), small interfering RNA (siRNA), peptides, antibodies, proteins, and quantum dots into virtually any cell type, including hard-to-transfect cells such as immune cells for cell therapies.
/by Daniel Granderson
https://d3lstfzn07k02o.cloudfront.net/wp-content/uploads/sites/12/2019/01/08092216/logo_ki.gif00Daniel Grandersonhttps://d3lstfzn07k02o.cloudfront.net/wp-content/uploads/sites/12/2019/01/08092216/logo_ki.gifDaniel Granderson2021-12-23 10:35:302021-12-23 10:41:4419 Need-To-Know Developments in Cell and Gene Therapy
Cell and Gene Therapy Business Outlook Editor Blake Middleton on
Significant CGT Developments at Meeting on the Mesa
The Meeting on the Mesa is going on. ( https://meetingonthemesa.com/agenda/) More than 1700 attendees are at the cell and gene therapy-focused meeting, along with Science Advisory Board, LabPulse and other members of the Science and Medicine group family. For subscribers of Cell and Gene Therapy Outlook, we will be providing analysis into developments at the meeting and the science behind some of the developments, as well as potential business applications.
As part of the meeting coverage. Blake Middleton, the editor of Cell and Gene Therapy Outlook, weighs in with his view of the latest developments:
Check back with us Friday, October 15th, for a review of the events at the cast.
From Science and Medicine Group, the owners of the popular INSTRUMENT BUSINESS OUTLOOK, comes a new twice-a-month newsletter dedicated to cell and gene therapy.
Cell and Gene Therapy Business Outlook offers the following:
Market Sizing and Forecasting of CAGT Markets: Each issue sizes up the market opportunity and projects the future revenues for a given therapeutic segment.
Keeping an Eye on Financing: With billions of investment dollars announced each year, Cell and Gene Therapy Business Outlook tracks who is getting financed (and the companies behind the financing) each issue. On a regular basis we will analyze trends in that financing.
News Briefs and Analysis of the Science That will Shape Tomorrow’s Business: Cell and Gene Therapy Business Outlook is designed to provide the most relevant news. With a focus on what the recent news of the day means for business, our curated news and news analysis means that you and your organization can be confident you won’t miss an important development in cell and gene therapy.
Deals Between CAGT Companies Tracked: Each issue’s “Recent Deals Table” tracks the important deals between stem cell companies as well as the deals they engage in (tech transfers, partnerships, mergers, distribution and other activities) with companies outside the industry.
Cell and Gene Therapy Tools: This newsletter will also report on developments, product launches and deals relating to the makers of cell and gene therapy manufacturing equipment and supplies.
With issues 2x a month, this newsletter dedicated to cell and gene therapy is the best way to keep up in this rapidly-developing and well financed field.
Convenient and Cost-Effective Seat-Based Pricing: Pricing depends on the number of users. Subscriptions can be as low as $2,200 annually for a limited one-person (single user) subscription. If more than one person will be reading, you can unlock access to other members of your organization. It’s easy to do: team subscription prices are as little as $4,995 annually for up to five readers.
/by Bruce Carlson
https://d3lstfzn07k02o.cloudfront.net/wp-content/uploads/sites/12/2019/01/08092216/logo_ki.gif00Bruce Carlsonhttps://d3lstfzn07k02o.cloudfront.net/wp-content/uploads/sites/12/2019/01/08092216/logo_ki.gifBruce Carlson2021-10-13 15:35:052021-10-18 08:17:31#Meeting on the Mesa / Cell and Gene Therapy Show Cast
19 Need-To-Know Developments in Cell and Gene Therapy
The following are recent developments in Cell and Gene Therapy, from Volume 1, Issue 13 of Cell and Gene Therapy Business Outlook, published December 22, 2021
#Meeting on the Mesa / Cell and Gene Therapy Show Cast
Cell and Gene Therapy Business Outlook Editor Blake Middleton on
Significant CGT Developments at Meeting on the Mesa
The Meeting on the Mesa is going on. ( https://meetingonthemesa.com/agenda/) More than 1700 attendees are at the cell and gene therapy-focused meeting, along with Science Advisory Board, LabPulse and other members of the Science and Medicine group family. For subscribers of Cell and Gene Therapy Outlook, we will be providing analysis into developments at the meeting and the science behind some of the developments, as well as potential business applications.
As part of the meeting coverage. Blake Middleton, the editor of Cell and Gene Therapy Outlook, weighs in with his view of the latest developments:
Check back with us Friday, October 15th, for a review of the events at the cast.
From Science and Medicine Group, the owners of the popular INSTRUMENT BUSINESS OUTLOOK, comes a new twice-a-month newsletter dedicated to cell and gene therapy.
Cell and Gene Therapy Business Outlook offers the following:
With issues 2x a month, this newsletter dedicated to cell and gene therapy is the best way to keep up in this rapidly-developing and well financed field.
Convenient and Cost-Effective Seat-Based Pricing: Pricing depends on the number of users. Subscriptions can be as low as $2,200 annually for a limited one-person (single user) subscription. If more than one person will be reading, you can unlock access to other members of your organization. It’s easy to do: team subscription prices are as little as $4,995 annually for up to five readers.